Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a biopharmaceutical company dedicated to the discovery, development, manufacturing, ...

Cell surface protein labeling supports precise characterization of immune checkpoints, receptors, and other therapeutic ...

Nurix entered into the collaboration with Seagen Inc., now part of Pfizer, in September 2023. Under the terms of the agreement, Nurix received an upfront payment of $60 million and became eligible to ...

Trispecific T-cell engagers target two tumor antigens or dual immune targets, aiming to reduce antigen-loss resistance and boost cancer killing beyond bispecifics.

Innovent Biologics, Inc. announced updated Phase 1 clinical data for IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma ...

Lung cancer remains the deadliest malignancy worldwide, and non-small cell lung cancer (NSCLC) accounts for roughly 85 ...

The open-label basket study will enrol patients with mesothelin-positive advanced refractory solid tumours, with the first ...

Researchers often use antibodies to detect specific molecules or biological markers, as they are remarkably precise at recognizing their targets.

Why Global Top‐Tier Teams Choose Chinese Research‐Reagent Brand?. Rigorous validation in metabolism, oncology immunology and gut‐brain‐axis research proves Cloud‐Clone antibodies' global‐competitive ...

Mirum Pharmaceuticals, Inc. announced the primary endpoint was met in the Phase 3 portion of the AZURE-1 study evaluating brelovitug, an investigational fully human monoclonal antibody that binds to ...

Creative Biolabs has expanded its specialized antibody portfolio targeting structural and envelope proteins from HIV-1, HIV-2, and HTLV-1.

Cancer antigens targeted by drug conjugates are restricted to the few membrane receptors (such as HER2 and TROP2) that ...